№ files_lp_3_process_9_34758
File format: docx Character count: 81517 File size: 134 KB
The document is a resubmission requesting the inclusion of darbepoetin alfa in the Australian Pharmaceutical Benefits Scheme for the treatment of moderate to severe chemotherapy-induced anaemia.
Year: 2023
Region / City: Australia
Topic: Oncology, Haematology, Pharmaceutical Submission
Document Type: Submission Request
Organisation: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Amgen Australian Pty Ltd
Target Audience: Healthcare professionals, Pharmaceutical industry
Period of Validity: Ongoing
Approval Date: N/A
Date of Changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Harnessing Multi-Omics Approaches to Elucidate the Role of Chinese Herbal Compounds in Chemotherapy-Induced Gastrointestinal Damage
Journal: World Journal of Gastrointestinal Oncology
Manuscript Type: Editorial
Authors: Chang Qiao; Hao-Xiang Zhang; Xiao-Tong Tian; Yan-Jing Zhang; De-Hui Li
Co-first authors: Chang Qiao; Hao-Xiang Zhang
Corresponding authors: Yan-Jing Zhang; De-Hui Li
Affiliated Institutions: Hebei University of Chinese Medicine; Guang’anmen Hospital, Academy of Chinese Medical Sciences; The First Affiliated Hospital of Hebei University of Chinese Medicine
Country: China
Region / City: Shijiazhuang, Hebei Province; Beijing
Research Field: Gastrointestinal Oncology; Integrative Medicine; Multi-omics Research
Keywords: Chinese herbal compounds; Gastrointestinal microenvironment; Chemotherapy; Multi-omics; Intestinal microecology
Funding: Government-funded Project of the Outstanding Talents Training Program in Clinical Medicine (ZF2023165); Key Research and Development Projects of Hebei Province (18277731D); Natural Science Foundation of Hebei Province (H202423105)
Received: September 16, 2024
Revised: November 11, 2024
Accepted: November 25, 2024
Published online: February 15, 2025
DOI: 10.4251/wjgo.v17.i2.101500
Article URL: https://www.wjgnet.com/1948-5204/full/v17/i2/101500.htm
Subject Focus: Mechanisms of Chinese herbal compounds in mitigating chemotherapy-induced gastrointestinal injury through multi-omics approaches
Institutions Involved: Graduate School of Hebei University of Chinese Medicine; Department of Oncology I and II, The First Affiliated Hospital of Hebei University of Chinese Medicine; Guang’anmen Hospital, Academy of Chinese Medical Sciences
Guidance on the Suggested Use of Medical Cannabis for Cancer and Chemotherapy-Induced Nausea and Vomiting
Year: 2023
Region / city: Utah
Topic: Medical Cannabis, Cancer Treatment
Document type: Guidance
Institution: Utah Cannabis Research Review Board, Department of Health and Human Services
Author: Utah Cannabis Research Review Board, Department of Health and Human Services staff
Target audience: Medical providers, patients, caregivers
Period of validity: Ongoing
Approval date: Not specified
Date of changes: Not specified
ASFOTASE ALFA RCH, Injection, 18 mg in 0.45 mL, 28 mg in 0.7 mL, 40 mg in 1 mL and 80 mg in 0.8 mL, vial Strensiq®, Alexion Pharmaceuticals Australasia Pty Ltd
Year: 2016
Region / city: Australia
Theme: Paediatric-onset Hypophosphatasia (HPP) treatment
Document type: Application submission
Organ / institution: Alexion Pharmaceuticals Australasia Pty Ltd
Author: Alexion Pharmaceuticals Australasia Pty Ltd
Target audience: Healthcare professionals, Pharmaceutical regulatory bodies
Period of validity: Ongoing
Approval date: 14 January 2016
Date of amendments: N/A
Appeal Hearing Decision on Olipudase Alfa for Treating Niemann-Pick Disease Types AB and B [ID3913], 24 May 2024
Year: 2024
Date of hearing: 24 May 2024
Country: England
Document type: Appeal hearing decision summary
Subject: Olipudase alfa for treating Niemann-Pick disease types AB and B (ASMD)
Institution: National Institute for Health and Care Excellence
Appeal body: Highly Specialised Technologies Appeal Panel
Appellant: Niemann-Pick UK
Legal adviser: DAC Beachcroft LLP
Grounds of appeal: Ground 1(a) – failure to act fairly; Ground 2 – unreasonableness in light of the evidence
Technology appraisal identifier: ID3913
Therapeutic area: Acid sphingomyelinase deficiency (ASMD)
Target population: People with ASMD types AB and B in England
Appeal Against Final Draft Guidance on Olipudase Alfa for Treating Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type AB and Type B [ID3913], 19 March 2024
Date: 19 March 2024
Organisation: Niemann-Pick UK (NPUK)
Address: Suite 2, Vermont House, Concord, Washington NE37 2SQ
Addressee: Dr Mark Chakravarty, Lead Non-executive Director for Appeals
Institution: National Institute for Health and Care Excellence
Subject: Appeal of Final Draft Guidance decision
Technology Appraised: Olipudase alfa
Indication: Acid sphingomyelinase deficiency (Niemann-Pick disease) type AB and type B
Reference ID: ID3913
Grounds for Appeal: Failure to act fairly; Unreasonable recommendation in light of evidence
Document Type: Formal appeal letter
Geographical Scope: United Kingdom
Cited Studies: Raebel et al., Orphanet Journal of Rare Diseases (2024); Fraser et al.
Alfa Romeo Giulia Wins Compasso d’Oro ADI Design Award – 22 June 2018
Date: 22 June 2018
Type of document: Press release
Subject: Compasso d’Oro ADI Design Award
Awarding body: Italian Industrial Design Association (ADI)
Award edition: 25th edition
Company: Alfa Romeo
Model: Alfa Romeo Giulia
Event location: Castello Sforzesco, Milan
Exhibition location: Museo Storico Alfa Romeo, Milan
Price information: From £29,880 OTR
Occasion: 108th anniversary of Alfa Romeo
Topics: DARBEPOETIN Chemotherapy-Induced ALFA